{"nctId":"NCT02114177","briefTitle":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis","startDateStruct":{"date":"2014-04"},"conditions":["Hepatitis C Virus Infection"],"count":310,"armGroups":[{"label":"Arm 1 (Simeprevir/Sofosbuvir)","type":"EXPERIMENTAL","interventionNames":["Drug: Simeprevir","Drug: Sofosbuvir"]},{"label":"Arm 2 (Simeprevir/Sofosbuvir)","type":"EXPERIMENTAL","interventionNames":["Drug: Simeprevir","Drug: Sofosbuvir"]}],"interventions":[{"name":"Simeprevir","otherNames":[]},{"name":"Simeprevir","otherNames":[]},{"name":"Sofosbuvir","otherNames":[]},{"name":"Sofosbuvir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hepatitis C virus (HCV) genotype 1a or 1b infection confirmed before randomization\n* Documentation of the presence or absence of a NS3 Q80K polymorphism in HCV genotype 1a infected participants before randomization\n* Documentation of the IL28B genotype before randomization\n* HCV ribonucleic acid level greater than 10,000 IU/mL at screening\n* Treatment-experienced participants must have at least 1 documented previous course of interferon-based regimen with or without ribavirin\n* Absence of cirrhosis in participants\n\nExclusion Criteria:\n\n* Evidence of clinical hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy)\n* Infection/co-infection with HCV non-genotype 1a or 1b\n* Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening)\n* Co-infection with hepatitis-B virus (hepatitis-B-surface-antigen positive)\n* Previously been treated with any direct acting anti-HCV agent (approved or investigational) for chronic HCV infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)","description":"Participants considered to have achieved SVR12, if the hepatitis C virus ribonucleic acid (HCV RNA) is less than (\\<) lower limit of quantification (LLOQ; 25 international unit per milliliter \\[IU/mL\\]) detectable or undetectable at 12 weeks after the actual end of study drug treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Sustained Virologic Response 4 Weeks After the Actual End of Treatment (SVR4)","description":"Participants considered to have achieved SVR4, if the hepatitis C virus ribonucleic acid (HCV RNA) is less than (\\<) lower limit of quantification (LLOQ; 25 international unit per milliliter \\[IU/mL\\]) detectable or undetectable at 4 weeks after the actual end of study drug treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)","description":"Participants considered to have achieved SVR24, if the hepatitis C virus ribonucleic acid (HCV RNA) is less than (\\<) lower limit of quantification (LLOQ; 25 international unit per milliliter \\[IU/mL\\]) detectable or undetectable at 24 weeks after the Actual end of study drug treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a On-treatment Virologic Response","description":"Ontreatment virologic response was determined by HCV RNA results satisfying a specified threshold. \\<LLOQ undetectable was considered as threshold at any time point. The LLOQ value is 25 IU/mL. EOT=End of Treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"93.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.92","spread":null},{"groupId":"OG001","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.26","spread":null},{"groupId":"OG001","value":"45.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.66","spread":null},{"groupId":"OG001","value":"34.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"98.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null},{"groupId":"OG001","value":"87.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Breakthrough","description":"Percentage of participants with greater than 1 log10 IU/mL increase in plasma Hepatitis C virus ribonucleic acid level from the lowest level reached (ie, lowest value measured in between baseline and current value), or a confirmed plasma HCV RNA level of greater than 100 IU/mL in participants whose plasma HCV RNA had previously been less than 25 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Relapse","description":"Percentage of participants who did not achieve sustained virologic response 12, have less than 25 IU/mL undetectable plasma HCV RNA at end of treatment, and greater than or equal to 25 IU/mL plasma HCV RNA during the follow-up phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hepatitis C Symptom and Impact Questionnaire 4 (HCV-SIQv4) Overall Body System Score (OBSS)","description":"HCVSIQv4 OBSS was a self-administered questionnaire that contained 33 items: 29 questions developed to assess severity or frequency of symptoms associated with HCV or its treatment, 3 questions regarding the impact of symptoms on work/school attendance, and 1 question regarding the impact of symptoms on daily activities. A symptom severity score (the mean of responses to the 29 symptom items); each symptom score was transformed to have a range from 0 to 100 (most severe). Higher HCV SIQv4 scores indicates worse symptom severity, more time missed from work/school, and more impairment in daily activities, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"0.94"},{"groupId":"OG001","value":"13.3","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.83"},{"groupId":"OG001","value":"-0.9","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.06"},{"groupId":"OG001","value":"-0.4","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"0.1","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"0.88"},{"groupId":"OG001","value":"-3.0","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"0.86"},{"groupId":"OG001","value":"-3.5","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"0.99"},{"groupId":"OG001","value":"-4.4","spread":"0.90"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fatigue Severity Scale (FSS) Score up to Follow-up Week 24","description":"The FSS was a self-administered questionnaire with 9 items developed to assess disabling fatigue that has been used extensively in studies of chronic HCV infection. Item responses were measured on a 7point Likert scale ranging from strongly disagree (1 point) to strongly agree (7 points). The 9 items were averaged to produce a total score; a lower total score indicates less severe fatigue. FSS scores have a range from 1 to 7 where higher scores indicate more severe fatigue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.13"},{"groupId":"OG001","value":"3.2","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.09"},{"groupId":"OG001","value":"-0.1","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.11"},{"groupId":"OG001","value":"-0.2","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"-0.1","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.12"},{"groupId":"OG001","value":"-0.4","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.11"},{"groupId":"OG001","value":"-0.4","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.13"},{"groupId":"OG001","value":"-0.5","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) Scores","description":"The CES-D scale assesses how often during the past week participants experienced 20 symptoms commonly associated with major depression. CES-D scores range from 0 (no symptoms) to 60 (all 20 symptoms most or all of the time during the past 5-7 days). The CES-D scores between 16 and 23 points indicate mild to moderate depressive illness while CES-D scores greater than or equal to 23 indicate probable major depressive illness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"0.72"},{"groupId":"OG001","value":"10.2","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.67"},{"groupId":"OG001","value":"-0.8","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.73"},{"groupId":"OG001","value":"-0.3","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"1.0","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"0.64"},{"groupId":"OG001","value":"-0.6","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"0.62"},{"groupId":"OG001","value":"-0.1","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"0.72"},{"groupId":"OG001","value":"-1.0","spread":"0.70"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol 5 Dimension (EQ-5D) Visual Analogue Scale","description":"The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a \"thermometer\" visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":"1.53"},{"groupId":"OG001","value":"76.7","spread":"1.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"1.31"},{"groupId":"OG001","value":"2.4","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"1.21"},{"groupId":"OG001","value":"2.7","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"2.5","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"1.34"},{"groupId":"OG001","value":"4.4","spread":"1.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"1.27"},{"groupId":"OG001","value":"3.9","spread":"1.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"1.51"},{"groupId":"OG001","value":"5.3","spread":"1.28"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":155},"commonTop":["Headache","Fatigue","Nausea","Diarrhoea","Constipation"]}}}